• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清内脏脂肪素和视黄醇结合蛋白-4 与青年 2 型糖尿病。

Visfatin and Retinol Binding Protein-4 in Young-Onset Type 2 Diabetes Mellitus.

机构信息

Department of Public Health, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan.

School of Public Health, College of Public Health, Taipei Medical University, Taipei City 11031, Taiwan.

出版信息

Medicina (Kaunas). 2023 Jul 9;59(7):1278. doi: 10.3390/medicina59071278.

DOI:10.3390/medicina59071278
PMID:37512089
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10386173/
Abstract

: The prevalence of type 2 diabetes mellitus in adolescents has increased rapidly in recent decades. However, the role of adipokines on pathophysiology in young-onset type 2 diabetes mellitus (YDM) is not clear. In this article, we explored the relationships between the adipokines (visfatin and retinol binding protein 4 (RBP4)) and metabolic syndrome (MetS) components in both YDM and late-onset type 2 diabetes mellitus (ODM). : There were 36 patients with YDM (23.6 ± 4.8 years) and 36 patients with ODM (54.3 ± 10.1 years) enrolled. Visfatin, RBP4, and MetS components were measured. The relationships between visfatin, RBP4 and MetS components were assessed in YDM and ODM. : The visfatin, but not the RPB4 level, was significantly higher in YDM than in ODM. After adjusting for age and body mass index, visfatin was not related to any MetS components except that there was a negative correlation with fasting plasma glucose (FPG). As for RPB4, triglyceride was found to be positively and FPG negatively related to RBP4 in YDM. However, in ODM, the only positive relationship that existed was between RBP4 and diastolic blood pressure. In conclusion, both visfatin and RBP4 had certain roles in diabetes and MetS although their relationships were different in YDM and ODM. Further studies are needed to explore their physiological and pathological effects in glucose metabolism.

摘要

青少年 2 型糖尿病的患病率在近几十年来迅速增加。然而,脂肪因子在青少年起病 2 型糖尿病(YDM)发病机制中的作用尚不清楚。在本文中,我们探讨了脂肪因子(内脏脂肪素和视黄醇结合蛋白 4(RBP4))与 YDM 和晚发 2 型糖尿病(ODM)代谢综合征(MetS)成分之间的关系。

共纳入 36 例 YDM 患者(23.6±4.8 岁)和 36 例 ODM 患者(54.3±10.1 岁)。检测内脏脂肪素、RBP4 和 MetS 成分。评估了 YDM 和 ODM 中内脏脂肪素、RBP4 与 MetS 成分之间的关系。

YDM 患者的内脏脂肪素水平明显高于 ODM 患者,而 RBP4 水平无显著差异。在校正年龄和体重指数后,内脏脂肪素与除空腹血糖(FPG)外的任何 MetS 成分均无相关性。至于 RBP4,在 YDM 中,三酰甘油与 RBP4 呈正相关,FPG 与 RBP4 呈负相关。然而,在 ODM 中,RBP4 仅与舒张压呈正相关。

总之,内脏脂肪素和 RBP4 在糖尿病和 MetS 中均有一定作用,但它们在 YDM 和 ODM 中的关系不同。需要进一步研究以探讨它们在葡萄糖代谢中的生理和病理作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4490/10386173/ace4cf83eef0/medicina-59-01278-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4490/10386173/195652cb0aae/medicina-59-01278-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4490/10386173/ace4cf83eef0/medicina-59-01278-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4490/10386173/195652cb0aae/medicina-59-01278-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4490/10386173/ace4cf83eef0/medicina-59-01278-g002.jpg

相似文献

1
Visfatin and Retinol Binding Protein-4 in Young-Onset Type 2 Diabetes Mellitus.血清内脏脂肪素和视黄醇结合蛋白-4 与青年 2 型糖尿病。
Medicina (Kaunas). 2023 Jul 9;59(7):1278. doi: 10.3390/medicina59071278.
2
Circulating retinol-binding protein 4 and metabolic syndrome in the elderly.老年人群中循环视黄醇结合蛋白4与代谢综合征
Wien Med Wochenschr. 2011 Nov;161(21-22):505-10. doi: 10.1007/s10354-011-0885-7. Epub 2011 Apr 4.
3
The adipokines and inflammatory marker in young type 2 diabetics with metabolic syndrome: A pilot study.年轻 2 型糖尿病合并代谢综合征患者的脂肪因子和炎症标志物:一项初步研究。
Obes Res Clin Pract. 2013 May-Jun;7(3):e206-10. doi: 10.1016/j.orcp.2011.12.002.
4
Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?血浆内视黄醇结合蛋白 4(RBP4)和内脏脂肪素水平与多囊卵巢综合征妇女的体重、代谢和激素紊乱有关吗?
Eur J Obstet Gynecol Reprod Biol. 2012 May;162(1):55-61. doi: 10.1016/j.ejogrb.2012.01.026. Epub 2012 Mar 6.
5
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.瘦人、肥胖者及糖尿病患者体内的视黄醇结合蛋白4与胰岛素抵抗
N Engl J Med. 2006 Jun 15;354(24):2552-63. doi: 10.1056/NEJMoa054862.
6
METFORMIN MODULATED ADIPOKINES BIOCHEMICAL MARKERS IN TYPE-2 DIABETES PATIENTS.二甲双胍对 2 型糖尿病患者脂联素生化标志物的调节作用。
Georgian Med News. 2024 May(350):95-97.
7
Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.肥胖儿童和青少年中的内脂素及其与胰岛素抵抗和代谢综合征的关联。
Scand J Clin Lab Invest. 2015 Apr;75(2):183-8. doi: 10.3109/00365513.2014.1003594. Epub 2015 Feb 27.
8
Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS.瘦型糖耐量正常多囊卵巢综合征妇女中内脂素和视黄醇结合蛋白 4 浓度。
Reprod Biomed Online. 2010 Jan;20(1):150-5. doi: 10.1016/j.rbmo.2009.10.016. Epub 2009 Oct 31.
9
The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis.在接受治疗的原发性骨质疏松症女性中,内脏脂肪素、视黄醇结合蛋白 4 和胰岛素抵抗对骨密度的影响。
Aging Clin Exp Res. 2019 Jun;31(6):889-895. doi: 10.1007/s40520-019-01206-6. Epub 2019 May 3.
10
Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes.视黄醇结合蛋白4与无2型糖尿病的非肥胖受试者的胰岛素抵抗及体脂分布相关。
J Clin Endocrinol Metab. 2007 May;92(5):1886-90. doi: 10.1210/jc.2006-1815. Epub 2007 Feb 13.

引用本文的文献

1
The role of inflammatory biomarkers RBP4, Lipocalin-2, and hsCRP in prediabetes and type 2 diabetes mellitus.炎症生物标志物视黄醇结合蛋白4、脂钙蛋白-2和高敏C反应蛋白在糖尿病前期和2型糖尿病中的作用。
J Med Biochem. 2025 Aug 21;44(5):1067-1073. doi: 10.5937/jomb0-57001.

本文引用的文献

1
Risk Correlation Analysis between Polycystic Ovary Syndrome (PCOS) and Serum Visfatin Levels in Middle-Aged Women: Systematic Review and Meta-Analysis.多囊卵巢综合征(PCOS)与中年女性血清内脂素水平的相关性分析:系统评价和荟萃分析。
Discov Med. 2023 Apr 1;35(175):168-177. doi: 10.24976/Discov.Med.202335175.17.
2
Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk.视黄醇和视黄醇结合蛋白 4 水平与心血管代谢疾病风险。
Circ Res. 2022 Sep 16;131(7):637-649. doi: 10.1161/CIRCRESAHA.122.321295. Epub 2022 Aug 26.
3
Association Between Circulating Retinol-Binding Protein 4 and Adverse Cardiovascular Events in Stable Coronary Artery Disease.
循环视黄醇结合蛋白4与稳定型冠状动脉疾病不良心血管事件之间的关联
Front Cardiovasc Med. 2022 Mar 17;9:829347. doi: 10.3389/fcvm.2022.829347. eCollection 2022.
4
Retinol-binding protein 4 in obesity and metabolic dysfunctions.肥胖和代谢功能紊乱中的视黄醇结合蛋白 4。
Mol Cell Endocrinol. 2021 Jul 1;531:111312. doi: 10.1016/j.mce.2021.111312. Epub 2021 May 4.
5
Elevated retinol binding protein 4 levels are associated with atherosclerosis in diabetic rats JAK2/STAT3 signaling pathway.糖尿病大鼠中视黄醇结合蛋白4水平升高与动脉粥样硬化及JAK2/STAT3信号通路有关。
World J Diabetes. 2021 Apr 15;12(4):466-479. doi: 10.4239/wjd.v12.i4.466.
6
Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.内脂素在蛋氨酸-胆碱缺乏饮食小鼠模型中会加剧肝脏炎症和纤维化。
J Gastroenterol Hepatol. 2021 Sep;36(9):2592-2600. doi: 10.1111/jgh.15465. Epub 2021 Feb 28.
7
The Role of Circulating RBP4 in the Type 2 Diabetes Patients with Kidney Diseases: A Systematic Review and Meta-Analysis.循环视黄醇结合蛋白 4 在伴有肾脏疾病的 2 型糖尿病患者中的作用:系统评价和荟萃分析。
Dis Markers. 2020 Oct 2;2020:8830471. doi: 10.1155/2020/8830471. eCollection 2020.
8
Young-onset type 2 diabetes mellitus - implications for morbidity and mortality.青年发病的2型糖尿病——对发病率和死亡率的影响
Nat Rev Endocrinol. 2020 Jun;16(6):321-331. doi: 10.1038/s41574-020-0334-z. Epub 2020 Mar 20.
9
Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up.长期随访中普通人群内脏脂肪素与肝脂肪变的相关性。
Horm Metab Res. 2019 Sep;51(9):602-607. doi: 10.1055/a-0897-8565. Epub 2019 May 27.
10
Circulating retinol-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease.循环视黄醇结合蛋白 4 与非酒精性脂肪性肝病的发生和消退有关。
Diabetes Metab. 2020 Apr;46(2):119-128. doi: 10.1016/j.diabet.2019.04.009. Epub 2019 May 9.